VivoSeq
Oncology

Peritoneum Cancer

28

Pipeline Programs

0

Active Trials

14

Companies Involved

Peritoneum Cancer is an emerging landscape with 28 programs across 14 companies. The most active players are Genzyme, a Sanofi Company, Javelin Pharmaceuticals, Boehringer Ingelheim. 15 therapies are approved with 5 more in late-stage development.

Pipeline Metrics

Competitive Density

50/100

Pipeline Velocity

0/100

Mech. Concentration

13/100

Completion Rate

100/100

Attrition Rate

0/100

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Programs by Phase

Modality Breakdown

96%

Small molecule

27 of 28 classified programs — the dominant modality here.

4%ALL OTHERSMonoclonal antibody14%

Small molecule leads; the ring shows all 28 classified programs, each share of the total. Modality classified for 100% of 28 pipeline programs.

Trial Status

1

clinical trials

Completed1 · 100%

Trial Activity

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)